Vaxart Inc
$ 0.63
0.72%
10 Apr - close price
- Market Cap 152,090,000 USD
- Current Price $ 0.63
- High / Low $ 0.65 / 0.62
- Stock P/E 9.00
- Book Value 0.36
- EPS 0.07
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.22 %
- 52 Week High 0.84
- 52 Week Low 0.26
About
Vaxart, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California.
Analyst Target Price
$3.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-19 | 2025-11-13 | 2025-08-13 | 2025-05-12 | 2025-03-12 | 2024-10-31 | 2024-08-08 | 2024-05-13 | 2024-03-14 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0.24 | -0.04 | -0.07 | -0.07 | -0.05 | -0.06 | -0.09 | -0.14 | -0.12 | -0.11 | -0.16 | -0.19 |
| Estimated EPS | -0.06 | -0.07 | -0.09 | -0.07 | -0.11 | -0.0933 | -0.03 | -0.14 | -0.14 | -0.18 | -0.18 | -0.19 |
| Surprise | 0.3 | 0.03 | 0.02 | 0 | 0.06 | 0.0333 | -0.06 | 0 | 0.02 | 0.07 | 0.02 | 0 |
| Surprise Percentage | 500% | 42.8571% | 22.2222% | 0% | 54.5455% | 35.6913% | -200% | 0% | 14.2857% | 38.8889% | 11.1111% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VXRT
2026-02-18 13:28:23
Vaxart (OTCQX: VXRT) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 4:00 PM ET. The virtual presentation will be available for replay on the company's investor relations website for 30 days after the event, and management will also hold one-on-one meetings. This continues Vaxart's active engagement with investors and scientists, following recent positive clinical data and earnings updates.
2026-02-03 20:58:42
Vaxart (VXRT) shares surged after the company announced positive data from its norovirus vaccine trial. The study demonstrated the vaccine's effectiveness against the GI.1 norovirus strain. This positive outcome marks a significant step forward for Vaxart's vaccine development.
2026-01-27 08:29:28
Vaxart (VXRT) recently published Phase 1 trial data for its oral bivalent norovirus vaccine, showing that vaccinated breastfeeding mothers transferred norovirus-specific antibodies to their infants via breastmilk, leading to infant stool IgA. This early evidence suggests a potential for passive immune protection in infants, reinforcing Vaxart's oral vaccine platform. Despite this scientific win, the company's investment narrative remains challenging due to historical losses, cash burn, and the need for further funding and partnerships to advance its programs.
2026-01-27 08:27:24
Vaxart Inc. recently published positive Phase 1 trial data for its oral bivalent norovirus vaccine, showing vaccine-induced antibodies in maternal breastmilk and infants' stool, suggesting passive infant protection. This scientific win strengthens Vaxart's oral vaccine platform narrative amidst its challenging financial history. However, despite this progress, Vaxart still faces significant risks related to cash burn, revenue contraction, and execution, with its stock valuation remaining a point of contention among investors.
2026-01-26 12:57:33
Vaxart, Inc. has emerged as a top performer in the Pharmaceuticals & Biotechnology sector, achieving a significant 59.48% stock return over the past six months. Other companies showing strong performance include Annaly Capital Management, Inc. with 16.77% and Mid Penn Bancorp, Inc. with 12.45%, while OptimizeRx Corp. experienced a decline. This analysis highlights the diverse investment landscape and varying sector performances in the current market.
2026-01-24 06:28:19
Wall Street Zen has upgraded Vaxart (NASDAQ:VXRT) to a "Buy" rating. Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant tablet vaccines. The company's stock opened at $0.67, with a market capitalization of $161.08 million, and institutional investors have recently adjusted their holdings.
